Victoza vs Ozempic: A Plain-Language Comparison Overview

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This overview lives in the PlexusDx Education Hub, our plain-language home for understanding GLP-1 options and the genetics that sit under them. Browse all Peptides & GLP-1 education

Independent editorial content. PlexusDx has no commercial relationship with the manufacturers of the products reviewed.

If you are just getting oriented, "Victoza vs Ozempic" can feel like alphabet soup. This overview keeps it simple: what each name refers to, how they relate as Novo Nordisk GLP-1 agonists, what the labels and trials cover, roughly what they cost as of April 2026, and why your own genetics frame the whole question before any prescription is written.

Getting oriented: what these two names actually mean

Ozempic (semaglutide, Novo Nordisk) and Victoza (liraglutide, Novo Nordisk) are both GLP-1 pathway compounds from the same manufacturer. Across the broader category, tirzepatide is a GIP/GLP-1 dual agonist; semaglutide, liraglutide, and dulaglutide are GLP-1-selective; and retatrutide is an investigational GLP-1/GIP/glucagon triple agonist not FDA-approved as of April 2026. Each engages the GLP-1 receptor and modulates gastric emptying, post-meal glucose, and satiety.

The paperwork: what the FDA has signed off on

Approval scope is worth knowing across the field: Ozempic (semaglutide) for type 2 diabetes (2017); Wegovy (semaglutide 2.4 mg) for chronic weight management (2021); Rybelsus (oral semaglutide) for type 2 diabetes (2019); Mounjaro (tirzepatide) for type 2 diabetes (2022); Zepbound (tirzepatide) for chronic weight management (2023) and obstructive sleep apnea (2024, SURMOUNT-OSA); Trulicity (dulaglutide) for type 2 diabetes (2014); and Victoza (liraglutide) for type 2 diabetes (2010). Retatrutide remains investigational.

What decades of trials do and don't tell you

Each molecule has its own program: STEP (semaglutide, weight), SUSTAIN and SELECT (semaglutide, diabetes and cardiovascular), SURMOUNT and SURPASS (tirzepatide), SURMOUNT-OSA (tirzepatide, sleep apnea), LEAD and LEADER (liraglutide), and AWARD (dulaglutide). Some head-to-head data exists — SUSTAIN 7 (semaglutide 1 mg vs dulaglutide 1.5 mg) and SURPASS-2 (tirzepatide vs semaglutide 1 mg in type 2 diabetes). Because populations and endpoints vary, treat the trials as per-study rather than a universal ranking.

Tolerability at a glance

All FDA-approved GLP-1 receptor agonists and GIP/GLP-1 dual agonists carry the boxed warning for thyroid C-cell tumor risk seen in rodent studies, and all are contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The most common effects are gastrointestinal — nausea, vomiting, diarrhea, constipation — usually during dose escalation. Rare serious events include pancreatitis, gallbladder events, and acute kidney injury with dehydration.

Budgeting for either option

As of April 2026, U.S. list prices across the FDA-approved brands range roughly $815 to $1,620 per month (manufacturer published pricing). What you pay depends heavily on insurance coverage, the FDA indication on the prescription, manufacturer savings-card eligibility, and whether a compounded alternative is available through a licensed compounding pathway.

Why your DNA frames the whole conversation

Before choosing between names, it helps to know the terrain. Variants in FTO (fat-mass and obesity-associated gene; appetite and adiposity set-point), GLP1R (encodes the GLP-1 receptor these compounds engage), MC4R (melanocortin receptor central to energy balance), and TCF7L2 (linked to glucose homeostasis and GLP-1 secretion) shape baseline metabolism. These are pathway-level markers — they do not predict response to Ozempic, Victoza, or any single compound.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols; it does not sell, distribute, or prescribe liraglutide. Whichever GLP-1 pathway compound you and your provider settle on, the underlying architecture is the same. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including FTO, GLP1R, MC4R, and TCF7L2 variants that shape your baseline GLP-1 and energy-balance biology. That is the test before you invest approach.

Related reading on PlexusDx: Ozempic for High Blood Pressure, Ozempic for Inflammation, Ozempic Qualifications, and Ozempic Conditions in the Education Hub.

Disclaimer: This is educational content. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols and does not sell, prescribe, or recommend liraglutide. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Start with the biology: take the Precision Peptide Genetic Test, or explore the Weight Management Protocols.

Frequently Asked Questions

In plain terms, how do Ozempic and Victoza relate?

They are two Novo Nordisk GLP-1-selective agonists built on different active molecules — semaglutide for Ozempic, liraglutide for Victoza. Neither one engages the GIP receptor. The most noticeable practical difference is dosing frequency: Ozempic is taken weekly, while Victoza is administered once daily.

If I'm just starting to research, which should I focus on?

Focus first on your own goals and history with a provider rather than the brand name. Trial evidence is per-study, and individual response varies. The upstream genetic pathway applies to both compounds, so understanding your metabolic terrain is useful before narrowing to any single option.

Does the genetic test recommend a specific drug?

No. The Precision Peptide Genetic Test does not predict response to Ozempic, Victoza, or any medication. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology — background context that applies regardless of which compound is eventually chosen.

Are the safety considerations the same for both?

Largely yes. Gastrointestinal symptoms are most common across the class and tend to peak during dose escalation, and both carry the boxed warning for thyroid C-cell tumor risk observed in rodent studies. Review your complete medical history with a provider before starting either.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.